Anticonvulsants Global Market Report 2024

“Anticonvulsants Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anticonvulsants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anticonvulsants? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The anticonvulsants market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Pyrimidinediones; Benzodiazepines; Fructose Derivatives; Aromatic Allylic Alcohols; Valproylamides; Carboxamides; Bromides; Other Types
• 2) By Drug Generation: First Generation; Second Generation; Third Generation
• 3) By Dosage: Capsule; Tablet; Cream; Liquid; Rectal Gel; Other Dosages
• 4) By Application: Migraine; Epilepsy; Neuropathic Pain; Anxiety; Fibromyalgia; Bipolar Disorder; Borderline Personality Disorder
• 5) By End-User: Hospitals; Clinics; Other End-Users
• Companies Mentioned: Eisai Co Ltd.; GlaxoSmithKline plc; Pfizer Inc.; Johnson & Johnson Services Inc .; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Anticonvulsants, also known as anti-seizure medications or antiepileptics, are a class of drugs designed to prevent and treat seizures or convulsions by regulating abnormal electrical activity in the brain. Additionally, these medications are employed to address conditions such as nerve pain and restless leg syndrome.

The primary types of anticonvulsants include pyrimidinediones, fructose derivatives, aromatic allylic alcohols, valproylamides, carboxamides, bromides, and others. Pyrimidines are heterocyclic aromatic organic compounds found in nucleic acids, proteins, starches, and other biological molecules. Anticonvulsants are categorized into first-generation, second-generation, and third-generation drugs, and are available in various dosage forms such as capsules, tablets, liquids, rectal gel, among others. They find applications in treating conditions such as migraine, epilepsy, neuropathic pain, anxiety, fibromyalgia, bipolar disorder, and borderline personality disorder. These medications are utilized in diverse end-user industries, including hospitals, clinics, and others.

The anticonvulsants market research report is one of a series of new reports from The Business Research Company that provides anticonvulsants market statistics, including anticonvulsants industry global market size, regional shares, competitors with a anticonvulsants market share, detailed anticonvulsants market segments, market trends and opportunities, and any further data you may need to thrive in the anticonvulsants industry. This anticonvulsants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticonvulsants market size has grown steadily in recent years. It will grow from $18.39 billion in 2023 to $19.08 billion in 2024 at a compound annual growth rate (CAGR) of 3.7%. The growth observed in the historical period can be attributed to several factors, including the increased prevalence of epilepsy, advancements in diagnostic capabilities, the expansion of indications for anticonvulsants, a focus on personalized medicine, and heightened awareness and education regarding the treatment of seizure disorders. These factors collectively contributed to the development and adoption of anticonvulsant medications during this period.

The anticonvulsants market size is expected to see steady growth in the next few years. It will grow to $21.75 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The anticipated growth in the forecast period can be attributed to several factors, including the ongoing increase in epilepsy cases, expanding applications in neuropsychiatry, the development of new anticonvulsant agents, a growing emphasis on mental health, and global health initiatives. Major trends expected in the forecast period include the development of pediatric applications and formulations, a shift towards extended-release formulations, increased adoption of generic versions of anticonvulsants, integration with digital health solutions, and ongoing research on the neuroprotective effects of these medications.

The upsurge in the prevalence of epilepsy is poised to propel the expansion of the anticonvulsants market in the foreseeable future. Epilepsy stands as a prevalent neurological disorder affecting the brain and often resulting in seizures. This chronic and non-communicable brain ailment affects individuals across all age groups. Anticonvulsants, a class of medications, are utilized to suppress seizures among individuals with epilepsy. They assist in managing epilepsy symptoms by curtailing abnormal electrical activity in the brain, which triggers seizures, although they do not offer a definitive cure for the condition. For instance, data from the World Health Organization in February 2023 revealed an estimated annual diagnosis of epilepsy in approximately 5 million individuals worldwide. In high-income countries, around 49 per 0.1 million people are diagnosed with epilepsy yearly, while in low- and middle-income countries, this figure escalates to as high as 139 per 0.1 million individuals. Hence, the escalating prevalence of epilepsy significantly propels the growth trajectory of the anticonvulsants market.

The burgeoning geriatric populace is anticipated to drive the expansion of the anticonvulsant market in the forthcoming years. The geriatric demographic pertains to the segment encompassing elderly individuals, typically defined as those aged 65 and above. Anticonvulsants play a pivotal role within this demographic, especially in managing seizures and epilepsy-common conditions among elderly individuals. For instance, projections from the World Health Organization in October 2022 indicate that by 2030, one in every six individuals globally will be aged 60 or older, totaling 1.4 billion people, up from 1 billion in 2020. Additionally, the global population aged 60 and older is expected to double by 2050, reaching 2.1 billion individuals. Notably, during the period from 2020 to 2050, there will be a surge of 426 million individuals aged 80 or older. Therefore, the swelling geriatric population significantly propels the expansion of the anticonvulsant market.

Product development emerges as a prominent trend gaining momentum within the anticonvulsants market. Leading companies in this sector are dedicatedly focused on innovating new products to fortify their market position and attain a competitive edge. For instance, Lupin Limited, an India-based pharmaceutical entity, introduced Rufinamide tablets USP, 200 mg and 400 mg, through an abbreviated new drug application in December 2022. Rufinamide, an anticonvulsant drug, is employed in conjunction with other medications to manage seizures in individuals afflicted with Lennox-Gastaut syndrome, a severe form of epilepsy characterized by varied seizures, behavioral disruptions, and developmental delays, typically originating in childhood.

Significant emphasis is placed on the introduction and approval of advanced drug solutions by major players operating in the anticonvulsants market to secure a competitive advantage. These novel drug solutions, upon approval by national regulatory bodies, aim to notably impact the availability of advanced therapies for patients grappling with seizures related to diverse syndromes. For instance, in March 2022, UCB, a Belgium-based biopharmaceutical firm, announced the approval by the U.S. Food and Drug Administration (FDA) for FINTEPLA (fenfluramine) oral solution CIV. This approval caters to treating seizures linked to Lennox-Gastaut syndrome in patients aged two years and above. Fenfluramine demonstrates efficacy in managing challenging seizure types such as drop seizures, characterized by sudden loss of muscular tone, leading to a limp state and an elevated risk of falling and injury. Fenfluramine, working through a distinct mechanism, complements and differs from existing epileptic drugs, enabling its continued use alongside current antiseizure regimens. The clinical trials evidenced statistically significant enhancements in patients with LGS when utilizing fenfluramine based on the Clinical Global Impression Scale (CG-I) in the global placebo-controlled phase 3 trial.

In May 2021, Jazz Pharmaceuticals Inc., an Ireland-based biopharmaceutical company, successfully acquired GW Pharmaceuticals plc for a total of $7.6 billion. This strategic acquisition serves to broaden, diversify, and enrich Jazz's portfolio business strategy by incorporating complementary therapies into its commercial portfolio and innovative pipeline. Additionally, the acquisition strengthens Jazz's neuroscience business through the addition of Epidiolex, a cannabis-based epilepsy treatment developed by GW Pharmaceuticals plc. The latter, headquartered in the UK, is a pharmaceutical company primarily engaged in the manufacturing of anticonvulsant medications.

Major companies operating in the anticonvulsants market report are Eisai Co Ltd., GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services Inc ., Novartis AG, Jazz Pharmaceuticals Inc., UCB SA, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc., Sanofi SA, Zydus Lifesciences Ltd., Lupin Limited, Ratiopharm Group, Kannalife Inc., Neuropathix Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Mylan N.V., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, AstraZeneca plc, Glenmark Pharmaceuticals Limited, Laurus Labs Limited, Biocon Limited, Recordati S.p.A., Neurocrine Biosciences Inc.

North America was the largest region in the Anticonvulsants market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global anticonvulsants market report during the forecast period. The regions covered in the anticonvulsants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anticonvulsants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The anticonvulsant market consists of sales of drugs such as phenobarbital, phenytoin, carbamazepine, levetiracetam, ethosuximide, clonazepam, diazepam, lorazepam, and midazolam. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.